JP2016518403A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518403A5
JP2016518403A5 JP2016512480A JP2016512480A JP2016518403A5 JP 2016518403 A5 JP2016518403 A5 JP 2016518403A5 JP 2016512480 A JP2016512480 A JP 2016512480A JP 2016512480 A JP2016512480 A JP 2016512480A JP 2016518403 A5 JP2016518403 A5 JP 2016518403A5
Authority
JP
Japan
Prior art keywords
trehalose
pharmaceutical
pharmaceutical formulation
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016512480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518403A (ja
JP6837835B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050411 external-priority patent/WO2014181333A2/en
Publication of JP2016518403A publication Critical patent/JP2016518403A/ja
Publication of JP2016518403A5 publication Critical patent/JP2016518403A5/ja
Application granted granted Critical
Publication of JP6837835B2 publication Critical patent/JP6837835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016512480A 2013-05-07 2014-05-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 Active JP6837835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
US61/820,278 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019075517A Division JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Publications (3)

Publication Number Publication Date
JP2016518403A JP2016518403A (ja) 2016-06-23
JP2016518403A5 true JP2016518403A5 (enExample) 2017-06-15
JP6837835B2 JP6837835B2 (ja) 2021-03-03

Family

ID=51022384

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016512480A Active JP6837835B2 (ja) 2013-05-07 2014-05-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2019075517A Pending JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2021095562A Pending JP2021152032A (ja) 2013-05-07 2021-06-08 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2023002536A Pending JP2023040211A (ja) 2013-05-07 2023-01-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2025036306A Pending JP2025087858A (ja) 2013-05-07 2025-03-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019075517A Pending JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2021095562A Pending JP2021152032A (ja) 2013-05-07 2021-06-08 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2023002536A Pending JP2023040211A (ja) 2013-05-07 2023-01-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2025036306A Pending JP2025087858A (ja) 2013-05-07 2025-03-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Country Status (14)

Country Link
US (4) US10493023B2 (enExample)
EP (2) EP2994145B1 (enExample)
JP (5) JP6837835B2 (enExample)
KR (1) KR20160009617A (enExample)
AU (5) AU2014264228A1 (enExample)
CA (2) CA2911399C (enExample)
CR (1) CR20150637A (enExample)
EA (1) EA201501054A1 (enExample)
IL (1) IL241757B (enExample)
MD (1) MD20150120A2 (enExample)
MX (1) MX2015015355A (enExample)
PE (1) PE20160012A1 (enExample)
SG (1) SG11201509030TA (enExample)
WO (1) WO2014181333A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
EA201501054A1 (ru) 2013-05-07 2016-04-29 Био Бласт Фарма Лтд. Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
US10736909B2 (en) 2016-02-08 2020-08-11 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
EA202090510A1 (ru) 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
WO2021067243A1 (en) 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
JP7701931B2 (ja) * 2020-02-13 2025-07-02 プリレニア ニューロセラピューティクス リミテッド プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法
WO2022013940A1 (ja) 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
CN116966192A (zh) * 2022-09-26 2023-10-31 西安文理学院 海藻糖在制备sca3疾病治疗药物中的应用
WO2024118797A1 (en) * 2022-11-30 2024-06-06 Seelos Therapeutics, Inc. Trehalose for treating huntington's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS4950521U (enExample) 1972-08-14 1974-05-02
JPS516109B2 (enExample) 1972-12-28 1976-02-25
JPS557829Y2 (enExample) 1974-07-01 1980-02-21
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
WO1997024129A1 (en) 1995-12-27 1997-07-10 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) * 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
US20050053666A1 (en) * 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
EP1600143B1 (en) 2003-02-13 2019-07-10 Hayashibara Co., Ltd. SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
EP1888095A4 (en) 2005-05-13 2009-08-26 Whitehead Biomedical Inst MODULATORS OF ALPHA-SYNUCLEIN INDUCED TOXICITY
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
CN102266274B (zh) 2005-08-11 2016-05-18 株式会社林原 胶原产生增强剂及其用途
EP1958612B1 (en) 2005-11-30 2014-07-02 The Nisshin OilliO Group, Ltd. Trehalose fatty acid ester composition
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
WO2007111214A1 (ja) 2006-03-27 2007-10-04 Otsuka Chemical Co., Ltd. トレハロース化合物および該化合物を含有する医薬
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
JP5258582B2 (ja) 2007-01-31 2013-08-07 株式会社糖鎖工学研究所 トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤
WO2008102563A1 (ja) 2007-02-23 2008-08-28 Next21 K.K. 血管攣縮の治療剤又は予防剤
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EP2214714A4 (en) * 2007-10-31 2011-01-12 Diffusion Pharmaceuticals Llc NEW CLASS OF THERAPEUTIC AGENTS THAT ENHANCE SMALL MOLECULE DELIVERY
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
WO2010008860A1 (en) * 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
EP2567963A1 (en) 2008-10-31 2013-03-13 Otsuka Chemical Co., Ltd. Trehalose compound, method for producing same, and pharmaceutical product containing the compound
CN102438652B (zh) * 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
CA3039907C (en) 2008-12-10 2022-12-13 Wista Laboratories Ltd. 3,6-disubstituted xanthylium salts
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
US20140066439A1 (en) * 2010-11-10 2014-03-06 Katholieke Universiteit Leuen, K.U.Leuven R&D Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
EP2721151B1 (en) 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US20220288096A1 (en) 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
EA201501054A1 (ru) 2013-05-07 2016-04-29 Био Бласт Фарма Лтд. Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
WO2015009961A1 (en) 2013-07-19 2015-01-22 Armagen Technologies, Inc. Compositions and methods related to structures that cross the blood brain barrier
US20170354666A1 (en) 2014-11-19 2017-12-14 Rush University Medical Center Compositions and methods for treating lysosomal disorders
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof
WO2017136533A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
WO2021067243A1 (en) 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2016518403A5 (enExample)
US12343342B2 (en) Methods for treating soft tissue sarcoma
US20220112277A1 (en) Anti-CGRP Antibody Formulation
KR101907411B1 (ko) 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
Malär et al. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
EP2938325B1 (en) Diclofenac composition
CN101677987A (zh) 不含吐温80的多西他赛的增溶制剂
EP3285758B1 (en) Co-crystal composition and its pharmaceutical use
JP2016516773A5 (enExample)
CN113164497A (zh) 免疫消融疗法
KR20220161403A (ko) 아리피프라졸 주사가능한 제제의 투여 방법
CN110035740A (zh) 稳定的水性辣椒素可注射制剂及其医学用途
JP2019530648A5 (enExample)
EP3881856A1 (en) Pharmaceutical composition for treating aplastic anemia
EP2974723A1 (en) Application of phthalide compound
US20220211663A1 (en) Nano co-delivery of quercetin and alantolactone promotes anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer
CN102481342A (zh) 使用促皮质素释放因子治疗癌症的方法
ES2979333T3 (es) Un nuevo compuesto de quinochalcona y usos del mismo para tratar el cáncer o la inflamación
JP2016537428A (ja) エフェドラ・アラタ抽出物及びその使用方法
EP4076417A1 (en) Caffeine citrate formulations
CN100444836C (zh) 含有丹参素钠的注射组合物
JP2020172471A (ja) ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物
EP3632446B3 (en) Immunoablative therapies
Kumar et al. Parenteral Suspensions: Stability Enhancing Liquid Dosage Forms
AU2022409776A1 (en) Pharmaceutical composition comprising p-boronophenylalanine